These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 28489919)

  • 1. Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
    Takahashi M; Komine K; Imai H; Okada Y; Saijo K; Takahashi M; Shirota H; Ohori H; Takahashi S; Chiba N; Mori T; Shimodaira H; Ishioka C
    PLoS One; 2017; 12(5):e0176972. PubMed ID: 28489919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
    Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
    Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.
    Lee EM; Rha SY; Lee J; Park KH; Ahn JH
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):635-42. PubMed ID: 21959979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].
    Yao Z; Yang S; Zhao Y; Yao S; Guo H; Liu Y
    Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):541-5. PubMed ID: 25327662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients.
    Tanaka K; Joyama S; Chuman H; Hiraga H; Morioka H; Yoshikawa H; Hosaka M; Takahashi M; Kubo T; Hatano H; Kaya M; Toguchida J; Nishida Y; Nagano A; Tsumura H; Iwamoto Y
    World J Surg Oncol; 2016 Dec; 14(1):306. PubMed ID: 27931230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
    Späth-Schwalbe E; Genvresse I; Koschuth A; Dietzmann A; Grunewald R; Possinger K
    Anticancer Drugs; 2000 Jun; 11(5):325-9. PubMed ID: 10912948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study.
    Hara H; Kawamoto T; Fukase N; Kawakami Y; Takemori T; Fujiwara S; Kitayama K; Nishida K; Kuroda R; Akisue T
    BMC Cancer; 2019 Jul; 19(1):725. PubMed ID: 31337342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.
    Kaya AO; Büyükberber S; Ozkan M; Alkiş N; Sevinc A; Ozdemir NY; Alici S; Esbah O; Berk V; Camci C; Ulas A; Coskun U; Benekli M;
    Asian Pac J Cancer Prev; 2012; 13(2):463-7. PubMed ID: 22524807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma.
    Tansir G; Rastogi S; Kumar A; Barwad A; Mridha AR; Dhamija E; Shamim SA; Bhatnagar S; Bhoriwal S
    BMC Cancer; 2023 Jul; 23(1):639. PubMed ID: 37422615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.
    Bay JO; Ray-Coquard I; Fayette J; Leyvraz S; Cherix S; Piperno-Neumann S; Chevreau C; Isambert N; Brain E; Emile G; Le Cesne A; Cioffi A; Kwiatkowski F; Coindre JM; Bui NB; Peyrade F; Penel N; Blay JY;
    Int J Cancer; 2006 Aug; 119(3):706-11. PubMed ID: 16496406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.
    Verschraegen CF; Arias-Pulido H; Lee SJ; Movva S; Cerilli LA; Eberhardt S; Schmit B; Quinn R; Muller CY; Rabinowitz I; Purdy M; Snyder D; Bocklage T
    Ann Oncol; 2012 Mar; 23(3):785-790. PubMed ID: 21746804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.
    García-Del-Muro X; López-Pousa A; Maurel J; Martín J; Martínez-Trufero J; Casado A; Gómez-España A; Fra J; Cruz J; Poveda A; Meana A; Pericay C; Cubedo R; Rubió J; De Juan A; Laínez N; Carrasco JA; de Andrés R; Buesa JM;
    J Clin Oncol; 2011 Jun; 29(18):2528-33. PubMed ID: 21606430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
    Fox E; Patel S; Wathen JK; Schuetze S; Chawla S; Harmon D; Reinke D; Chugh R; Benjamin RS; Helman LJ
    Oncologist; 2012; 17(3):321. PubMed ID: 22363068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
    Davis EJ; Chugh R; Zhao L; Lucas DR; Biermann JS; Zalupski MM; Feng M; Wong SL; Jacobson J; Zyczynski L; Reinke D; Metko G; Baker LH; Schuetze SM
    Eur J Cancer; 2015 Sep; 51(13):1794-802. PubMed ID: 26066736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study.
    Choi Y; Yun MS; Lim SH; Lee J; Ahn JH; Kim YJ; Park KH; Park YS; Lim HY; An H; Suh DC; Kim YH
    Cancer Res Treat; 2018 Jan; 50(1):175-182. PubMed ID: 28361521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine and docetaxel for metastatic soft tissue sarcoma - a single center experience.
    Schmitt T; Kosely F; Wuchter P; Schmier JW; Ho AD; Egerer G
    Onkologie; 2013; 36(7-8):415-20. PubMed ID: 23921760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study.
    Merimsky O; Meller I; Flusser G; Kollender Y; Issakov J; Weil-Ben-Arush M; Fenig E; Neuman G; Sapir D; Ariad S; Inbar M
    Cancer Chemother Pharmacol; 2000; 45(2):177-81. PubMed ID: 10663634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients.
    Qi WX; He AN; Tang LN; Shen Z; Lin F; Yao Y
    Jpn J Clin Oncol; 2012 May; 42(5):427-31. PubMed ID: 22450929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.
    Leu KM; Ostruszka LJ; Shewach D; Zalupski M; Sondak V; Biermann JS; Lee JS; Couwlier C; Palazzolo K; Baker LH
    J Clin Oncol; 2004 May; 22(9):1706-12. PubMed ID: 15117993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306.
    Kataoka K; Tanaka K; Mizusawa J; Kimura A; Hiraga H; Kawai A; Matsunobu T; Matsumine A; Araki N; Oda Y; Fukuda H; Iwamoto Y;
    Jpn J Clin Oncol; 2014 Aug; 44(8):765-9. PubMed ID: 24916336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.